Blue Bird Corporation (NASDAQ:BLBD – Get Free Report) Director Daniel Mark Thau bought 300 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $65.09 per share, for a total transaction of $19,527.00. Following the transaction, the director directly owned 8,696 shares in the company, valued at approximately $566,022.64. This represents a 3.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Blue Bird Stock Up 1.0%
Shares of NASDAQ BLBD traded up $0.66 during midday trading on Wednesday, hitting $65.31. 325,926 shares of the company’s stock were exchanged, compared to its average volume of 441,991. The firm’s fifty day simple moving average is $61.08 and its 200-day simple moving average is $55.41. The company has a market cap of $2.07 billion, a PE ratio of 16.04, a P/E/G ratio of 1.02 and a beta of 1.38. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.83 and a quick ratio of 1.27. Blue Bird Corporation has a twelve month low of $37.68 and a twelve month high of $81.51.
Blue Bird (NASDAQ:BLBD – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.12. The firm had revenue of $352.64 million for the quarter, compared to the consensus estimate of $335.23 million. Blue Bird had a return on equity of 53.68% and a net margin of 8.91%.The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.96 EPS. Research analysts predict that Blue Bird Corporation will post 4.35 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on BLBD
Institutional Trading of Blue Bird
A number of institutional investors have recently modified their holdings of BLBD. JPMorgan Chase & Co. raised its holdings in Blue Bird by 185.6% during the third quarter. JPMorgan Chase & Co. now owns 925,852 shares of the company’s stock worth $53,283,000 after purchasing an additional 601,690 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Blue Bird during the third quarter worth $10,932,000. Allspring Global Investments Holdings LLC raised its holdings in Blue Bird by 12.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 409,872 shares of the company’s stock worth $19,166,000 after purchasing an additional 46,801 shares during the last quarter. UBS Group AG raised its holdings in Blue Bird by 161.7% during the fourth quarter. UBS Group AG now owns 277,796 shares of the company’s stock worth $13,056,000 after purchasing an additional 171,642 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Blue Bird by 285.4% during the fourth quarter. SG Americas Securities LLC now owns 101,855 shares of the company’s stock worth $4,787,000 after purchasing an additional 75,428 shares during the last quarter. 93.59% of the stock is currently owned by hedge funds and other institutional investors.
About Blue Bird
Blue Bird Corporation (NASDAQ: BLBD) is a leading manufacturer of buses and mass transportation vehicles headquartered in Fort Valley, Georgia. The company’s core business encompasses the design, engineering, and production of school buses and activity buses, with a product lineup that includes conventional (Type C) models, transit-style (Type D) models and specialty configurations for special-needs and activity transport. In recent years, Blue Bird has expanded its offerings to include zero-emission electric school buses, reflecting its commitment to advanced propulsion technologies and environmental sustainability.
Established in 1927, Blue Bird has built a legacy of safety and reliability in student transportation.
Featured Articles
- Five stocks we like better than Blue Bird
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
- The Great Cloud Divide: How AI Is Reshuffling the Software Deck
Receive News & Ratings for Blue Bird Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blue Bird and related companies with MarketBeat.com's FREE daily email newsletter.
